Call for FOREUM career research grants

FOREUM is committed to promote the best talents in the field of rheumatic and musculoskeletal diseases (RMD). Consistent with these goals FOREUM issues a new call that aims to fund excellent young researchers promoting innovative ideas and supporting high quality research projects covering basic and clinical science projects related to RMDs.

Scientific excellence is the key eligibility criterion for this career research grant initiative, which aims to foster independent science and intends to develop new research leaders in the field.

FOREUM career research grants are intended to fund excellent young scientists with an already existing track record in RMD research. The grant aims at supporting the initiation of an innovative independent research project for a period of maximal 36 months that allows sustained career development of the applicant to become a future group leader.

The applicant must be a talented early-career scientist who has already produced high-level supervised work. She/he must be an MD or PhD, who is appropriately linked to RMD research in Europe. It is anticipated that applicants can work independently and have the potential to become a research leader in the RMD research community. The applicant must be awarded her/his PhD or MD no longer than 8 years ago. Maternity or paternity leaves will be considered.
The researcher’s institution must declare how it intends to support the applicant with respect to her/his position, protected research time, lab space or access the clinical data. Integrating knowledge, experiences and techniques from other European centers involved in RMD research is also stimulated. Participation of patient research partners is strongly encouraged to underline the importance of the project for the patients.

Important note
This grant is meant for young scientists staying in their own research centre and NOT going on an exchange.
If you are interested in an exchange programme, please read more here.

Call timeline
The next call will be announced in 2021.